Hepatic Oncology最新文献

RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells. RTA - 408诱导p38依赖性细胞凋亡并抑制肝癌细胞活力。

IF 1.3

Hepatic Oncology Pub Date : 2026-12-01 Epub Date: 2026-04-27 DOI: 10.1080/20450923.2026.2659967

Wei-Chieh Chen, Yoon Bin Chong, Hung-Pei Tsai, Tzu-Ting Tseng, Chen-Yu Wang, Shih-Hsun Kuo, Sheau-Fang Yang, Chun-Chieh Wu

{"title":"RTA‑408 induces p38‑dependent apoptosis and suppresses cell viability in hepatocellular carcinoma cells.","authors":"Wei-Chieh Chen, Yoon Bin Chong, Hung-Pei Tsai, Tzu-Ting Tseng, Chen-Yu Wang, Shih-Hsun Kuo, Sheau-Fang Yang, Chun-Chieh Wu","doi":"10.1080/20450923.2026.2659967","DOIUrl":"https://doi.org/10.1080/20450923.2026.2659967","url":null,"abstract":"Introduction: Hepatocellular carcinoma (HCC) remains difficult to treat, highlighting the need for new therapeutic strategies. RTA-408 (omaveloxolone), a synthetic oleanane triterpenoid and NRF2 pathway modulator, has reported anticancer activity, but its mechanisms in HCC are not fully understood.Materials and methods: HepG2 and PLC/PRF/5 (PP5) cells were treated with RTA-408 for 24 h. Cell viability, apoptosis, and signaling pathways were evaluated using MTT assay, Annexin V/7-AAD flow cytometry, and western blotting. The role of p38 signaling was examined using the p38 inhibitor SB203580.Results: RTA-408 reduced cell viability in a concentration-dependent manner and increased apoptosis in both cell lines. At 600 nM, apoptosis increased to approximately 18.43% in HepG2 cells and 24.71% in PP5 cells. RTA-408 increased p38 phosphorylation and NRF2 expression and was accompanied by LC3B and p62 accumulation and elevated cleaved caspase-3. Inhibition of p38 partially restored cell viability and reduced apoptosis.Conclusion: RTA-408 suppresses HCC cell survival through a p38-dependent stress response associated with NRF2 activation and LC3B/p62 accumulation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"13 1","pages":"2659967"},"PeriodicalIF":1.3,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13123068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147785047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Qualitative research to understand the patient experience with advanced and/or metastatic hepatocellular carcinoma. 定性研究以了解晚期和/或转移性肝细胞癌患者的经历。

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-10-23 DOI: 10.1080/20450923.2025.2567741

Sally Lanar, Asma Kefsi, Maria Armaou, Fallon Jones-Lemmons, Marie de La Cruz, Kelly Lipman, Benoit Arnould, Cécile Gousset

{"title":"Qualitative research to understand the patient experience with advanced and/or metastatic hepatocellular carcinoma.","authors":"Sally Lanar, Asma Kefsi, Maria Armaou, Fallon Jones-Lemmons, Marie de La Cruz, Kelly Lipman, Benoit Arnould, Cécile Gousset","doi":"10.1080/20450923.2025.2567741","DOIUrl":"10.1080/20450923.2025.2567741","url":null,"abstract":"Aim: The present study aimed to explore the patient experience in advanced and/or metastatic hepatocellular carcinoma (HCC).Materials & methods: A multi-phase research design was followed that included a targeted literature review (TLR), interviews with clinicians, and interviews with patients. Patient interviews were analyzed using an iterative, thematic analysis approach. An assessment of the conceptual saturation of all spontaneously patient-reported signs and symptoms was conducted.Results: Ten patient-centric qualitative studies were identified in the TLR. Five United States (US) clinicians and 15 US patients participated in semi-structured interviews, conducted via video conferencing, lasting approximately 60 minutes each. The five most commonly reported symptoms were fatigue, weight loss, weakness, reduction in appetite, and sleep disturbance. Furthermore, HCC impacted all aspects of patients' lives, including physical functioning, social and family functioning, emotional functioning, physical activities, and activities of daily living. The concepts were mostly similar across the different data sources. A patient-centric conceptual model was developed based on the TLR and patient interviews.Conclusion: The study provides an in-depth description of signs/symptoms and impacts in advanced and/or metastatic HCC that can support the identification of suitable patient-reported outcome measures. Separate investigation is needed to distinguish between disease impacts and treatment impacts.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2567741"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12562793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145349097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of hepatocellular carcinoma prior to liver transplantation: latest developments. 肝移植前肝细胞癌的处理：最新进展。

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-08-23 DOI: 10.1080/20450923.2025.2549676

Antoine Robert, Thomas M Hunold, Neehar D Parikh

{"title":"Management of hepatocellular carcinoma prior to liver transplantation: latest developments.","authors":"Antoine Robert, Thomas M Hunold, Neehar D Parikh","doi":"10.1080/20450923.2025.2549676","DOIUrl":"10.1080/20450923.2025.2549676","url":null,"abstract":"Hepatocellular carcinoma (HCC) is a highly morbid malignancy that is a leading cause of death in patients with cirrhosis or chronic hepatitis B. Liver transplantation is considered a curative therapy for HCC, with 5-year survival rates exceeding 75%. Current allocation policy in the US restricts transplant to patients with early HCC, and priority for transplant is granted after 6 months on the waitlist, thus patients often require therapies for cancer control while awaiting liver transplantation. The most commonly applied therapies for HCC in patients awaiting liver transplantation are locoregional therapies, including ablative, radiation, and arterial based therapies. Using these therapies patient can be effectively bridged or downstaged to liver transplantation, however there are risks of progressive liver decompensation with locoregional therapies in patients with portal hypertension. There are emerging data for the use of immune checkpoint inhibitor-based immunotherapies in the treatment of HCC. While there has been concern for rejection with the administration of immunotherapy prior to liver transplantation, early data suggest that the risk can be minimized with sufficient washout time prior to liver transplantation. Herein we aim to review management strategies for patients with HCC awaiting liver transplantation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2549676"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic arterial infusion chemotherapy in patients with unresectble hepatocellular carcinoma: 3-year survival update. 肝动脉输注化疗在不可切除的肝细胞癌患者中的应用：3年生存更新。

IF 1.2

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-06-17 DOI: 10.1080/20450923.2025.2516994

Shiguang Chen, Wenchang Yu, Xiaolong Wang, Weifu Liu

引用次数: 0

Clinical management of liver cancer patients with immune checkpoint inhibitors treatment. 免疫检查点抑制剂治疗肝癌患者的临床管理。

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-10-30 DOI: 10.1080/20450923.2025.2578079

Johnny C W Yau, Landon L Chan, Stephen L Chan

{"title":"Clinical management of liver cancer patients with immune checkpoint inhibitors treatment.","authors":"Johnny C W Yau, Landon L Chan, Stephen L Chan","doi":"10.1080/20450923.2025.2578079","DOIUrl":"10.1080/20450923.2025.2578079","url":null,"abstract":"The treatment paradigm of hepatocellular carcinoma (HCC) has evolved with the emergence of immune checkpoint inhibitors (ICIs). Two ICI-based regimens have gained regulatory approval worldwide in unresectable HCC as first line treatment based on the IMBrave150 and HIMALAYA trial. Other regimens such as camrelizumab-rivoceranib and ipilimumab-nivolumab also demonstrated improvement in overall survival as compared to multi-targeted agents in recent phase III clinical trials. With the growing amount of evidence, it is imperative for clinicians to decide the most suitable ICI therapy for each patient based on their disease status and tolerability. Furthermore, ICI in combination with locoregional treatment such as transarterial chemoembolization (TACE) has been shown to prolong the progression-free survival as compared to TACE alone. In early-stage HCC, the role of ICI has been studied in both the adjuvant and neoadjuvant setting. In this narrative review, we will highlight the major advancement of ICI in different stages of HCC and their implication in real world practice. The unmet need in the special population of liver cancer patients and the management of immune-related hepatitis will also be addressed.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2578079"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12578309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy. 推进肝细胞癌的精准医学：液体活检、免疫微环境、单核苷酸多态性和转化治疗的当前挑战和未来方向

IF 1.2

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-04-22 DOI: 10.1080/20450923.2025.2493457

Miho Akabane, Yuki Imaoka, Jun Kawashima, Timothy M Pawlik

{"title":"Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy.","authors":"Miho Akabane, Yuki Imaoka, Jun Kawashima, Timothy M Pawlik","doi":"10.1080/20450923.2025.2493457","DOIUrl":"https://doi.org/10.1080/20450923.2025.2493457","url":null,"abstract":"Hepatocellular carcinoma (HCC) remains a health concern characterized by heterogeneity and high mortality. Surgical resection, radiofrequency ablation, trans-arterial chemoembolization, and liver transplantation offer potentially curative treatments for early-stage disease, but recurrence remains high. Most patients present with advanced-stage HCC, where locoregional therapies are less effective, and systemic treatments-primarily multi-kinase inhibitors and immune checkpoint inhibitors-often yield limited responses. Precision medicine aims to tailor therapy to molecular and genetic profiles, yet its adoption in HCC is hindered by inter-/intra-tumoral heterogeneity and limited biopsy availability. Advances in molecular diagnostics support reintroducing tissue sampling to better characterize genetic, epigenetic, and immunological features. Liquid biopsy offers a minimally invasive method for capturing real-time tumor evolution, overcoming spatial and temporal heterogeneity. Artificial intelligence and machine learning are revolutionizing biomarker discovery, risk stratification, and treatment planning by integrating multi-omics data. Immunological factors such as tumor-infiltrating lymphocytes, natural killer cells, macrophages, and fibroblasts have emerged as determinants of HCC progression and treatment response. Conversion therapy-combining systemic agents with locoregional treatments-has showndemonstrated promise in downstaging unresectable HCC. Ongoing efforts to refine biomarker-driven approaches and optimize multi-modality regimens underscore precision medicine's potential to improve outcomes. PubMed (January 2002-February 2025) was searched for relevant studies.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2493457"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144055635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two-way increased-risk associations between hepatobiliary cancers and other malignancies: a population-based study. 胆道癌和其他恶性肿瘤之间的双向风险增加关联：一项基于人群的研究

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-10-16 DOI: 10.1080/20450923.2025.2570115

Huibiao Deng, Xiaoyuan Gong, Meiling Wang, Qingqing Zhang, Fei Li, Xiaohong Wu, Qidi Zhang

{"title":"Two-way increased-risk associations between hepatobiliary cancers and other malignancies: a population-based study.","authors":"Huibiao Deng, Xiaoyuan Gong, Meiling Wang, Qingqing Zhang, Fei Li, Xiaohong Wu, Qidi Zhang","doi":"10.1080/20450923.2025.2570115","DOIUrl":"10.1080/20450923.2025.2570115","url":null,"abstract":"Aim: Our aim was to examine two-way increased-risk associations between hepatobiliary cancers and malignancies that develop before/after them.Patients and methods: Data of USA from Surveillance, Epidemiology, and End Results (SEER), 17 registries (2000-2021) were analyzed using different statistical methods.Results: Overall, 5,574,604 cancer cases were identified, which included hepatocellular carcinoma (HCC) (59,764), cancer of bile duct (including Ampulla of Vater) (22,735), cancer of gallbladder (10,155), and other malignancies (5,481,950). We found two-way increased-risk associations for the following eight cancer pairs: HCC-upper aerodigestive tract, HCC-esophagus, HCC-stomach, HCC-anus, HCC-bile duct, HCC-lung/bronchus, HCC-non-Hodgkin lymphoma, and bile duct-stomach. After HCC or bile duct cancer, the standardized incidence ratios (SIRs) (95% CI) of the corresponding second primary malignancies (SPMs) were 1.88 (1.61-2.18), 1.46 (1.07-1.96), 1.59 (1.25-2.00), 3.53 (2.31-5.18), 3.98 (3.15-4.97), 1.54 (1.41-1.69), 2.2 (1.92-2.52), and 2.30 (1.59-3.21), respectively. In reverse order (i.e. HCC or bile duct cancer as SPM), the SIRs (95% CI) were 1.48 (1.34-1.62), 1.43 (1.06-1.90), 1.49 (1.22-1.79), 1.76 (1.27-2.36), 1.62 (1.03-2.44), 1.39 (1.27-1.53), 1.31 (1.19-1.44), and 1.73 (1.31-2.24), respectively.Conclusion: The major shared etiologic factors for the identified cancer pairs were life-style (smoking, alcohol use, and excess body weight), chronic infections (hepatitis B and C viruses), and genetic risks.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2570115"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145303963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies. HES V2.0在HCC检测方面超过GALAD：多维生物标志物评分和研究综述

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-04-30 DOI: 10.1080/20450923.2025.2494446

Fouad Jaber, Hashem B El-Serag

{"title":"HES V2.0 surpasses GALAD for HCC detection: a review of multi-dimensional biomarker scores and studies.","authors":"Fouad Jaber, Hashem B El-Serag","doi":"10.1080/20450923.2025.2494446","DOIUrl":"10.1080/20450923.2025.2494446","url":null,"abstract":"This was a narrative review of select studies published through September of 2024. We review the shift toward multi-dimensional scores such as HCC early detection screening (HES), GALAD, ASAP, and mt-HBT represents a significant advancement in biomarker research for hepatocellular carcinoma (HCC) detection. Unlike single biomarker approaches, these scores integrate various clinical and biochemical factors to enhance predictive accuracy by reflecting different complementary aspects of disease progression and HCC oncogenesis. Proper testing and validation of biomarker scores in phase 3 biomarker studies is essential before wide use can be recommended. We also review the comparative performance of biomarker scores in phase 3 studies. The new version of HES (HES V2.0) which includes AFP, AFP L3, DCP, and changes in their levels the past one year, if available, in addition to age, platelets, albumin, ALT and underlying liver disease etiology outperforms GALAD in detecting early-stage HCC with overall 6.7% higher sensitivity, and ASAP with 13.4%-18.0% higher sensitivity, both at fixed 90% specificity. HES V2.0 is a leading candidate biomarker score for prospective testing in clinical studies of early HCC detection.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2494446"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation. 美国早期HCC患者切除或消融治疗的现实世界治疗模式和结果

IF 1.3

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-07-24 DOI: 10.1080/20450923.2025.2530377

Neehar D Parikh, Ravi Patel, Jenny Hu, Heide A Stirnadel-Farrant, Nehemiah Kebede, Cindy Wang, Kirema Garcia-Reyes

{"title":"Real-world treatment patterns and outcomes in patients with early-stage HCC in the US treated with resection or ablation.","authors":"Neehar D Parikh, Ravi Patel, Jenny Hu, Heide A Stirnadel-Farrant, Nehemiah Kebede, Cindy Wang, Kirema Garcia-Reyes","doi":"10.1080/20450923.2025.2530377","DOIUrl":"10.1080/20450923.2025.2530377","url":null,"abstract":"Aim: Real-world outcomes in early-stage hepatocellular carcinoma (eHCC) are not well characterized. We aimed to evaluate treatment patterns and long-term outcomes in patients with eHCC treated with resection or ablation in the United States.Materials and methods: We conducted a retrospective study with Optum's de-identified Market Clarity Data. Patient characteristics, treatment patterns, and overall survival (OS) were assessed in adults with eHCC treated with resection or ablation between July 2016 and March 2021.Results: Of 649 patients who met inclusion criteria, 59.3%, 37.3%, and 3.4% underwent ablation only, resection only, or both, as their initial treatment, respectively. Median age was 64.0 years; most patients were male (72.9%) and White (65.5%). Subsequent treatment was received in 47.1% of patients. The median (quartile 1-3) time to first subsequent treatment was 216 (89.3-414.3) days. The most common subsequent treatments included embolization (22.7%) and ablation (15.6%). In total, 35.7% of patients died post-index. Median OS was 67.7 (95% CI: 56.4-not estimable) months. Estimated 24-month OS was 79.0% (95% CI: 75.0-82.0).Conclusions: Our results highlight the need for post-treatment surveillance and the potential role for neoadjuvant and/or adjuvant treatments to improve outcomes in patients with eHCC treated with resection or ablation.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2530377"},"PeriodicalIF":1.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape. 循环肿瘤DNA在胆道癌中的整合：新兴景观。

IF 1.2

Hepatic Oncology Pub Date : 2024-12-31 Epub Date: 2024-10-09 DOI: 10.1080/20450923.2024.2403334

Joy A Awosika, Cecilia Monge, Tim F Greten

{"title":"Integration of circulating tumor DNA in biliary tract cancer: the emerging landscape.","authors":"Joy A Awosika, Cecilia Monge, Tim F Greten","doi":"10.1080/20450923.2024.2403334","DOIUrl":"10.1080/20450923.2024.2403334","url":null,"abstract":"Precision medicine has emerged as a cornerstone in cancer treatment revolutionizing our approach across malignancies. Molecular profiling of biliary tract cancers (BTCs) has changed the treatment landscape positively by prolonging survival in an aggressively fatal malignancy in its advanced stages. The acquisition of tissue tumor DNA for genomic analysis in BTC is often anatomically challenging, limited by quantity and quality. In response, ctDNA has emerged as a noninvasive means of molecular profiling. The utility of both plasma and bile ctDNA has been explored in several studies demonstrating the high mutation detection rates and the ability to isolate targetable mutations when present. In addition, the concordance between plasma and tissue DNA provides validity in utilizing ctDNA results to infer treatment decisions. Analysis of ctDNA in BTC has also provided prognostic information and facilitated evaluation of clonal evolution with ease of serial measurements. Insight into novel mechanisms of resistance to targeted therapies are being uncovered in ctDNA. As research endeavors continue to deepen our understanding in the field particularly in the space of ctDNA surveillance after curative intent, the tremendous progress made so far has enabled integration of ctDNA into the clinical practice of BTCs.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"11 1","pages":"2403334"},"PeriodicalIF":1.2,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0